Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
Conditions
- HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Interventions
- DRUG: BEBT-209 capsules
- DRUG: BEBT-209 Placebo capluses
- DRUG: Fulvestrant Injection
Sponsor
BeBetter Med Inc
Collaborators